Biogen reports $2.5B Q1 revenue, +2% YoY, with non-GAAP EPS of $3.57, up 18%. LEQEMBI’s 78% 18-month persistence rate and a new high-dose SPINRAZA FDA approval signal commercial and pipeline …
Biogen reports $2.5B Q1 revenue, +2% YoY, with non-GAAP EPS of $3.57, up 18%. LEQEMBI’s 78% 18-month persistence rate and a new high-dose SPINRAZA FDA approval signal commercial and pipeline …
You must be logged in to post a comment.